Director Kevin F. McLaughlin filed a Form 144 notice of proposed sale of 7,000 shares of Vericel Corp common stock, with an approximate sale date of November 10, 2026, through Fidelity Brokerage Services LLC.

Key Highlights

  • Seller and role: Kevin F. McLaughlin, listed as a Director of Vericel Corp, is the person for whose account the securities are to be sold.
  • Shares proposed for sale: 7,000 shares of Vericel Corp common stock, with an aggregate market value of $408,730.00 as reported in the filing.
  • Acquisition method: The 7,000 shares were acquired on November 10, 2026, via a stock option exercise from the issuer, with cash payment on the same date.
  • Shares outstanding: The filing reports 51,029,770 shares of common stock outstanding.
  • Prior sales: McLaughlin sold 7,000 shares of common stock on August 12, 2026, with gross proceeds of $311,693.20, according to the filing's three-month sales history.
  • Rule 10b5-1 plan: The filing indicates a plan adoption date of May 12, 2025, with the notice date listed as November 10, 2026.
  • Exchange: The securities are listed on NASDAQ, and the company trades under NASDAQ:VCEL as identified in the filing context consistent with the issuer name Vericel Corp.

McLaughlin's Proposed Stock Sale: Acquisition and Filing Details

According to the Form 144 filing, Vericel Corp director Kevin F. McLaughlin is proposing to sell 7,000 shares of common stock through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917. The aggregate market value of the proposed sale is listed as $408,730.00. The approximate date of sale is noted as November 10, 2026, the same date the notice was filed.

The filing discloses that the 7,000 shares to be sold were acquired on November 10, 2026, through a stock option exercise from the issuer, with cash paid on that same date. The filing further notes that the sale is being conducted under a Rule 10b5-1 trading plan, with the plan adoption date recorded as May 12, 2025. By signing the notice, the seller's representative represents, as of the plan adoption date, that McLaughlin did not know of any material adverse information regarding Vericel Corp's current and prospective operations that had not been publicly disclosed.

In the three-month sales history required by the form, the filing reports that McLaughlin sold 7,000 shares of common stock on August 12, 2026, generating gross proceeds of $311,693.20. The filing lists Vericel Corp's address as 25 Blue Sky Drive, Burlington, Massachusetts 01803, with SEC File Number 001-35280. The notice was signed by Daniel Tucci as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Kevin McLaughlin.

What Was Disclosed

Vericel Corp director Kevin F. McLaughlin filed a Form 144 notice proposing the sale of 7,000 shares of common stock, valued at $408,730.00, acquired via stock option exercise on November 10, 2026, under a Rule 10b5-1 plan adopted May 12, 2025.